<DOC>
	<DOCNO>NCT00203424</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness bevacizumab plus erlotinib follow radical prostatectomy .</brief_summary>
	<brief_title>Treatment Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib</brief_title>
	<detailed_description>This study explore anti-tumor activity adjuvant bevacizumab plus erlotinib select group prostate cancer patient deem high risk early relapse follow radical prostatectomy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Karnofsky performance status &gt; 80 Patients must localize , organconfined prostate cancer document physical examination , CT scan , bone scan , must undergo radical prostatectomy . Post RP must document node negative prostate cancer . Pretreatment granulocyte count &gt; 1500/mm3 , hemoglobin &gt; 9.0 g/dL , platelet count &gt; 100,000/mm3 , Normal PT PTT Serum creatinine &lt; 2.0 mg/dL Adequate hepatic function serum bilirubin &lt; upper limit normal ( ULN ) , AST ALT &lt; 1.5x ULN , alkaline phosphatase &lt; 2.5x ULN . Highrisk prostate cancer define preRP prostate specific antigen level &gt; 15 ng/dL Gleason score &gt; 8 Stage T3 disease positive surgical margin Men childbearing potential must willing consent use effective contraception treatment 3 month thereafter Evidence small cell ( neuroendocrine ) tumor Evidence metastatic disease Prior administration immunotherapy , biological therapy , hormonal therapy radiation therapy prostate cancer Active secondary malignancy ( basal cell carcinoma skin ) Serious , nonhealing wound , ulcer , bone fracture . Clinically significant cardiovascular disease ( e.g. , blood pressure &gt; 150/100 mmHg , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication , clinically significant peripheral vascular disease . Patients history myocardial infarction stroke within last 6 month exclude . Presence seizure control standard medical therapy Active infection require parenteral antibiotic time first administration study drug Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study ; minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 . Current , recent ( within 4 week precede Day 0 ) , plan participation another experimental drug study Inability comply study visit followup schedule procedures History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . Urine protein : creatinine ration &gt; 1.0 screen Evidence bleed diathesis coagulopathy . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior Day 0 . Presence central nervous system brain metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>